Patients with coagulation factor(s) deficiency who use coagulation therapy are susceptible to forming inhibitors against coagulation factor(s). In this survey we detected factor V and VIII inhibitor in ten patients with combined deficiency of factors V and VIII from north east of Iran (Khorassan province). It was revealed in our survey that eight patients had both factor V and factor VIII i...

patients with coagulation factor(s) deficiency who use coagulation therapy are susceptible to forming inhibitors against coagulation factor(s). in this survey we detected factor v and viii inhibitor in ten patients with combined deficiency of factors v and viii from north east of iran (khorassan province). it was revealed in our survey that eight patients had both factor v and factor viii inhib...

This review summarizes current data on the pathomechanisms and new genetic findings of combined factor V and VIII deficiency (CF5F8D). Congenital haemorrhagic disorders characterized by deficiency of two clotting factors comprise an interesting group. Among dual coagulation disorders, CF5F8D is the most common type. For the first time combined factor V and VIII deficiency (F5F8D) was reported b...

this review summarizes current data on the pathomechanisms and new genetic findings of combined factor v and viii deficiency (cf5f8d). congenital haemorrhagic disorders characterized by deficiency of two clotting factors comprise an interesting group. among dual coagulation disorders, cf5f8d is the most common type. for the first time combined factor v and viii deficiency (f5f8d) was reported b...

background: factor v g1691a (fv leiden), fii ga20210, and methylenetetrahydrofolate reductase (mthfr) c677t mutations are the most common genetic risk factors for thromboembolism in the western countries. however, there is rare data in iran about cerebral venous and sinus thrombosis (cvst) patients. the aim of this study was to evaluate the frequency of common genetic thrombophilic factors in c...

introduction : activated protein c (apc) inactivates factor v by cleavage of its heavy chain at arg306, arg506, arg679, and lys994. mutational changes, which abolish apc cleavage sites, may predispose thrombosis by altering the inactivation process of factor v.  factor v leiden (arg506glu) has been demonstrated as a strong risk factor for thrombosis. in the current study, we have studied whethe...

Factor V deficiency secondary to inhibitors is extremely rare and can be caused by a wide collection of exposures such as bovine thrombin and beta lactamase antibiotics. The management of factor V deficiency with inhibitor is a condition treated based on case reports due to the rarity of this condition. We describe a complicated case of an elderly patient with severe factor V deficiency with hi...